Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing therapies for neurodegenerative diseases, announced that its President and CEO, Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will focus on the scientific rationale for treating Alzheimer's disease as a multi-protein disorder and detail Annovis' approach of simultaneously targeting multiple neurotoxic proteins with its lead drug candidate, buntanetap.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of several neurotoxic proteins, including amyloid precursor protein (APP), amyloid beta, tau, alpha-synuclein, and TDP-43. This mechanism of action targets the underlying causes of neurodegeneration, aiming to halt disease progression and improve cognitive and motor functions in patients. The drug is currently being evaluated in a pivotal Phase 3 clinical trial for Alzheimer's disease.
Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on developing treatments for Alzheimer's disease (AD) and Parkinson's disease (PD). The company's approach addresses the multifactorial nature of these conditions, which involve the accumulation of multiple toxic proteins. By targeting these proteins simultaneously, Annovis hopes to provide a more effective therapeutic option than current single-target therapies.
For more information about Annovis Bio and its pipeline, visit the company's website at www.annovisbio.com. The full press release is available at https://ibn.fm/kZ2Z4. Additional news and updates on ANVS can be found in the company's newsroom at https://ibn.fm/ANVS.
The presentation at Fierce Biotech Week underscores the growing recognition of Alzheimer's as a complex disease involving multiple proteins. Annovis' multi-protein targeting strategy represents a shift from conventional approaches that focus on a single protein, such as amyloid beta alone. If successful, buntanetap could offer a more comprehensive treatment for Alzheimer's and potentially other neurodegenerative diseases.
Investors and researchers will be watching closely for updates from the Phase 3 trial, which could provide critical data on the drug's efficacy and safety. The company's focus on addressing multiple neurotoxic proteins simultaneously positions it at the forefront of innovative Alzheimer's research.
